Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the third quarter ended December 31, 2021. For the third quarter, the company reported sales was INR 174.31 million compared to INR 251.99 million a year ago. Revenue was INR 175.54 million compared to INR 263.99 million a year ago.

Net loss was INR 3.29 million compared to INR 18.95 million a year ago. Basic loss per share from continuing operations was INR 0.08 compared to INR 0.44 a year ago. Diluted loss per share from continuing operations was INR 0.08 compared to INR 0.44 a year ago.